Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction

Nicholas W. Choong, Ann M. Mauer, Daniel C. Haraf, Mark K. Ferguson, Alan B. Sandler, Kenneth Kesler, Paul A S Fishkin, Rafat H. Ansari, James Wade, Stuart A. Krauss, David F. Sciortino, Mitchell C. Posner, Masha Kocherginsky, Philip C. Hoffman, Livia Szeto, Everett E. Vokes

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We performed a phase II trial to evaluate a docetaxel-based regimen in locoregionally advanced esophageal cancer. Untreated stage II-IVa esophageal cancer patients with performance status 0-2 were included. Tumor resectability was determined prior to initiation of study. Induction docetaxel (75 mg/m 2) and cisplatin (75 mg/m 2) day 1 with prophylactic filgrastim was delivered every 21 days for 3 cycles. Subsequent concomitant chemoradiotherapy (CRT) utilized weekly docetaxel (20 mg/m 2) and concurrent radiotherapy (2 Gy/day) in resectable/resected patients (50 Gy) and in unresectable patients (66 Gy). A total of 78 patients (15 squamous cell carcinoma, 60 adenocarcinoma, 3 mixed/undifferentiated; 68 men, 10 women; median age 61 years) were accrued. The regimen was administered to 59 (76%) potentially resectable patients and 13 (17%) unresectable patients; 6 patients (8%) received the regimen post-operatively. Response rate in 66 evaluable patients following induction chemotherapy was 30%. Sixty-nine patients underwent CRT. Ten patients had disease progression during CRT. Forty-five out of 59 potentially resectable patients underwent esophagectomy after CRT, and 42 patients had complete tumor resection with negative margins. Eighteen out of 59 patients who were potentially resectable patients had pathologic complete response (pCR-31%). Grade 3/4 toxicity during induction chemotherapy included leucopenia, neutropenia, vomiting, and neuropathy. Esophagitis was the predominant toxicity during CRT. Median overall survival was 11.4 months for unresectable patients, 14.3 months for resectable patients and 10.4 months for patients who received the regimen post-operatively (log-rank P = 0.2492). Docetaxel-based CRT regimen is active and tolerable in esophageal cancer. The observed pCR in the potentially resectable group indicates good local control.

Original languageEnglish
JournalMedical Oncology
Volume28
Issue numberSUPPL. 1
DOIs
StatePublished - Dec 2011

Fingerprint

docetaxel
Esophagogastric Junction
Chemoradiotherapy
Esophagus
Carcinoma
Esophageal Neoplasms
Induction Chemotherapy

Keywords

  • Docetaxel
  • Esophagus cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Cite this

Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. / Choong, Nicholas W.; Mauer, Ann M.; Haraf, Daniel C.; Ferguson, Mark K.; Sandler, Alan B.; Kesler, Kenneth; Fishkin, Paul A S; Ansari, Rafat H.; Wade, James; Krauss, Stuart A.; Sciortino, David F.; Posner, Mitchell C.; Kocherginsky, Masha; Hoffman, Philip C.; Szeto, Livia; Vokes, Everett E.

In: Medical Oncology, Vol. 28, No. SUPPL. 1, 12.2011.

Research output: Contribution to journalArticle

Choong, NW, Mauer, AM, Haraf, DC, Ferguson, MK, Sandler, AB, Kesler, K, Fishkin, PAS, Ansari, RH, Wade, J, Krauss, SA, Sciortino, DF, Posner, MC, Kocherginsky, M, Hoffman, PC, Szeto, L & Vokes, EE 2011, 'Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction', Medical Oncology, vol. 28, no. SUPPL. 1. https://doi.org/10.1007/s12032-010-9658-1
Choong, Nicholas W. ; Mauer, Ann M. ; Haraf, Daniel C. ; Ferguson, Mark K. ; Sandler, Alan B. ; Kesler, Kenneth ; Fishkin, Paul A S ; Ansari, Rafat H. ; Wade, James ; Krauss, Stuart A. ; Sciortino, David F. ; Posner, Mitchell C. ; Kocherginsky, Masha ; Hoffman, Philip C. ; Szeto, Livia ; Vokes, Everett E. / Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. In: Medical Oncology. 2011 ; Vol. 28, No. SUPPL. 1.
@article{d98d3b34beb04f5b974ab31bd8941178,
title = "Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction",
abstract = "We performed a phase II trial to evaluate a docetaxel-based regimen in locoregionally advanced esophageal cancer. Untreated stage II-IVa esophageal cancer patients with performance status 0-2 were included. Tumor resectability was determined prior to initiation of study. Induction docetaxel (75 mg/m 2) and cisplatin (75 mg/m 2) day 1 with prophylactic filgrastim was delivered every 21 days for 3 cycles. Subsequent concomitant chemoradiotherapy (CRT) utilized weekly docetaxel (20 mg/m 2) and concurrent radiotherapy (2 Gy/day) in resectable/resected patients (50 Gy) and in unresectable patients (66 Gy). A total of 78 patients (15 squamous cell carcinoma, 60 adenocarcinoma, 3 mixed/undifferentiated; 68 men, 10 women; median age 61 years) were accrued. The regimen was administered to 59 (76{\%}) potentially resectable patients and 13 (17{\%}) unresectable patients; 6 patients (8{\%}) received the regimen post-operatively. Response rate in 66 evaluable patients following induction chemotherapy was 30{\%}. Sixty-nine patients underwent CRT. Ten patients had disease progression during CRT. Forty-five out of 59 potentially resectable patients underwent esophagectomy after CRT, and 42 patients had complete tumor resection with negative margins. Eighteen out of 59 patients who were potentially resectable patients had pathologic complete response (pCR-31{\%}). Grade 3/4 toxicity during induction chemotherapy included leucopenia, neutropenia, vomiting, and neuropathy. Esophagitis was the predominant toxicity during CRT. Median overall survival was 11.4 months for unresectable patients, 14.3 months for resectable patients and 10.4 months for patients who received the regimen post-operatively (log-rank P = 0.2492). Docetaxel-based CRT regimen is active and tolerable in esophageal cancer. The observed pCR in the potentially resectable group indicates good local control.",
keywords = "Docetaxel, Esophagus cancer, Radiotherapy",
author = "Choong, {Nicholas W.} and Mauer, {Ann M.} and Haraf, {Daniel C.} and Ferguson, {Mark K.} and Sandler, {Alan B.} and Kenneth Kesler and Fishkin, {Paul A S} and Ansari, {Rafat H.} and James Wade and Krauss, {Stuart A.} and Sciortino, {David F.} and Posner, {Mitchell C.} and Masha Kocherginsky and Hoffman, {Philip C.} and Livia Szeto and Vokes, {Everett E.}",
year = "2011",
month = "12",
doi = "10.1007/s12032-010-9658-1",
language = "English",
volume = "28",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction

AU - Choong, Nicholas W.

AU - Mauer, Ann M.

AU - Haraf, Daniel C.

AU - Ferguson, Mark K.

AU - Sandler, Alan B.

AU - Kesler, Kenneth

AU - Fishkin, Paul A S

AU - Ansari, Rafat H.

AU - Wade, James

AU - Krauss, Stuart A.

AU - Sciortino, David F.

AU - Posner, Mitchell C.

AU - Kocherginsky, Masha

AU - Hoffman, Philip C.

AU - Szeto, Livia

AU - Vokes, Everett E.

PY - 2011/12

Y1 - 2011/12

N2 - We performed a phase II trial to evaluate a docetaxel-based regimen in locoregionally advanced esophageal cancer. Untreated stage II-IVa esophageal cancer patients with performance status 0-2 were included. Tumor resectability was determined prior to initiation of study. Induction docetaxel (75 mg/m 2) and cisplatin (75 mg/m 2) day 1 with prophylactic filgrastim was delivered every 21 days for 3 cycles. Subsequent concomitant chemoradiotherapy (CRT) utilized weekly docetaxel (20 mg/m 2) and concurrent radiotherapy (2 Gy/day) in resectable/resected patients (50 Gy) and in unresectable patients (66 Gy). A total of 78 patients (15 squamous cell carcinoma, 60 adenocarcinoma, 3 mixed/undifferentiated; 68 men, 10 women; median age 61 years) were accrued. The regimen was administered to 59 (76%) potentially resectable patients and 13 (17%) unresectable patients; 6 patients (8%) received the regimen post-operatively. Response rate in 66 evaluable patients following induction chemotherapy was 30%. Sixty-nine patients underwent CRT. Ten patients had disease progression during CRT. Forty-five out of 59 potentially resectable patients underwent esophagectomy after CRT, and 42 patients had complete tumor resection with negative margins. Eighteen out of 59 patients who were potentially resectable patients had pathologic complete response (pCR-31%). Grade 3/4 toxicity during induction chemotherapy included leucopenia, neutropenia, vomiting, and neuropathy. Esophagitis was the predominant toxicity during CRT. Median overall survival was 11.4 months for unresectable patients, 14.3 months for resectable patients and 10.4 months for patients who received the regimen post-operatively (log-rank P = 0.2492). Docetaxel-based CRT regimen is active and tolerable in esophageal cancer. The observed pCR in the potentially resectable group indicates good local control.

AB - We performed a phase II trial to evaluate a docetaxel-based regimen in locoregionally advanced esophageal cancer. Untreated stage II-IVa esophageal cancer patients with performance status 0-2 were included. Tumor resectability was determined prior to initiation of study. Induction docetaxel (75 mg/m 2) and cisplatin (75 mg/m 2) day 1 with prophylactic filgrastim was delivered every 21 days for 3 cycles. Subsequent concomitant chemoradiotherapy (CRT) utilized weekly docetaxel (20 mg/m 2) and concurrent radiotherapy (2 Gy/day) in resectable/resected patients (50 Gy) and in unresectable patients (66 Gy). A total of 78 patients (15 squamous cell carcinoma, 60 adenocarcinoma, 3 mixed/undifferentiated; 68 men, 10 women; median age 61 years) were accrued. The regimen was administered to 59 (76%) potentially resectable patients and 13 (17%) unresectable patients; 6 patients (8%) received the regimen post-operatively. Response rate in 66 evaluable patients following induction chemotherapy was 30%. Sixty-nine patients underwent CRT. Ten patients had disease progression during CRT. Forty-five out of 59 potentially resectable patients underwent esophagectomy after CRT, and 42 patients had complete tumor resection with negative margins. Eighteen out of 59 patients who were potentially resectable patients had pathologic complete response (pCR-31%). Grade 3/4 toxicity during induction chemotherapy included leucopenia, neutropenia, vomiting, and neuropathy. Esophagitis was the predominant toxicity during CRT. Median overall survival was 11.4 months for unresectable patients, 14.3 months for resectable patients and 10.4 months for patients who received the regimen post-operatively (log-rank P = 0.2492). Docetaxel-based CRT regimen is active and tolerable in esophageal cancer. The observed pCR in the potentially resectable group indicates good local control.

KW - Docetaxel

KW - Esophagus cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84655176759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84655176759&partnerID=8YFLogxK

U2 - 10.1007/s12032-010-9658-1

DO - 10.1007/s12032-010-9658-1

M3 - Article

VL - 28

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - SUPPL. 1

ER -